| Titolo |
Pubblicato in |
Anno |
| Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study |
JOURNAL OF NEUROLOGY |
2025 |
| Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience |
JOURNAL OF NEUROLOGY |
2025 |
| Complement inhibitor therapy in thymoma-associated myasthenia gravis: a real-world experience |
FRONTIERS IN IMMUNOLOGY |
2025 |
| Emergent role of complement inhibitors in myasthenic crisis: Understanding why, when and how |
CLINICAL NEUROLOGY AND NEUROSURGERY |
2025 |
| Chronic inflammatory demyelinating polyneuropathy and HEV antibody
status: A case-control study from Lazio, Italy |
JOURNAL OF THE NEUROLOGICAL SCIENCES |
2024 |
| Serum neurofilament light chain levels correlate with small fiber related parameters in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) |
NEUROLOGICAL SCIENCES |
2024 |
| Muscle MRI as a biomarker of disease activity and progression in myotonic dystrophy type 1: a longitudinal study |
JOURNAL OF NEUROLOGY |
2024 |
| Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors
Focus on Chronic Toxicities |
NEUROLOGY® NEUROIMMUNOLOGY & NEUROINFLAMMATION |
2024 |
| Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study |
LANCET NEUROLOGY |
2023 |
| Comparison of quantitative muscle ultrasound and whole-body muscle MRI in facioscapulohumeral muscular dystrophy type 1 patients |
NEUROLOGICAL SCIENCES |
2023 |
| Quantitative sensory testing and skin biopsy findings in late‐onset ATTRv pre‐symptomatic carriers: relationships with predicted time of disease onset (PADO) |
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM |
2023 |
| Prominent mitochondrial pathology in a case of refractory dermatomyositis: coincidence or concause? |
NEUROLOGICAL SCIENCES |
2023 |
| Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors |
NEUROLOGICAL SCIENCES |
2023 |
| Muscle MRI in immune-mediated necrotizing myopathy (IMNM). implications for clinical management and treatment strategies |
JOURNAL OF NEUROLOGY |
2022 |
| Distal upper limb involvement in myasthenia-myositis association |
NEUROLOGICAL SCIENCES |
2022 |
| Nerve high-resolution ultrasound in a 2-years follow-up of radial nerve palsy related to humeral shaft fractures |
JOURNAL OF NEUROSURGICAL SCIENCES |
2022 |
| Changes of clinical, neurophysiological and nerve ultrasound characteristics in CIDP over time: a 3-year follow-up |
JOURNAL OF NEUROLOGY |
2021 |
| Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension |
NEUROLOGY |
2021 |
| Skin biopsy and quantitative sensory assessment in an Italian cohort of ATTRv patients with polyneuropathy and asymptomatic carriers: possible evidence of early non-length dependent denervation |
NEUROLOGICAL SCIENCES |
2021 |
| Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT). a multicentre, randomised, placebo-controlled, phase 3 trial |
LANCET NEUROLOGY |
2021 |
